Fortrea Says China Gaining Importance in Rare Disease Trials
Fortrea says China is becoming more important in global rare disease trials.
Related stories
WABI Raises $55 Million at $1.25 Billion Valuation
WABI raised $55 million at a $1.25 billion valuation, following strong early demand.
L impact | EQUITY | Oct 29, 2026, 12:55 PM UTC
Newmark Group Reports Q3 Net Income of $48.9 Million
Newmark Group reported net income of $48.9 million for the third quarter.
M impact | EQUITY | Oct 29, 2026, 12:54 PM UTC
HGTECH Q3 net profit rises 17.03% year over year
M impact | EQUITY | Oct 29, 2026, 12:54 PM UTC
Donegal Group Publishes Q3 2026 Earnings Call Transcript
M impact | EQUITY | Oct 29, 2026, 12:54 PM UTC
Inner Mongolia Yili Q3 Net Profit Falls 5.6% Y/Y
M impact | EQUITY | Oct 29, 2026, 12:53 PM UTC
GATX Reports Third-Quarter Results
M impact | EQUITY | Oct 29, 2026, 12:53 PM UTC